Theravance Biopharma Inc. (TBPH)
8.64
0.11 (1.29%)
At close: Jan 15, 2025, 3:59 PM
8.61
-0.35%
After-hours Jan 15, 2025, 04:00 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Revenue | 57.42M | 51.35M | 55.31M | 71.86M | 73.41M | 60.37M | 15.39M | 48.65M | 42.13M | 11.69M | 226.00K | 130.15M | 14.85M |
| Cost of Revenue | 40.62M | 6.59M | 7.29M | 260.95M | 219.25M | 715.00K | 6.03M | 2.89M | 4.66M | 4.06M | 120.58M | 114.00M | 3.84M |
| Gross Profit | 16.80M | 44.76M | 48.02M | -189.10M | -145.83M | 59.66M | 9.36M | 45.75M | 37.47M | 7.63M | -120.35M | 16.15M | 11.01M |
| Operating Income | -56.03M | -91.96M | -257.78M | -297.76M | -251.91M | -238.75M | -260.12M | -180.47M | -181.90M | -232.54M | -156.28M | -9.57M | -109.33M |
| Interest Income | 9.12M | 8.54M | 1.11M | 2.83M | 8.39M | 11.97M | 4.96M | 1.31M | 631.00K | 1.86M | n/a | n/a | n/a |
| Pretax Income | -49.27M | -92.81M | -199.58M | -286.54M | -241.68M | -226.09M | -271.71M | -180.56M | -181.27M | -230.67M | -156.28M | -9.57M | -109.33M |
| Net Income | -55.19M | -92.82M | -199.43M | -278.02M | -236.46M | -215.52M | -285.40M | -190.67M | -182.22M | -237.04M | -156.28M | -9.57M | -109.33M |
| Selling & General & Admin | 70.09M | 67.07M | 99.30M | 108.66M | 106.08M | 97.06M | 95.59M | 84.51M | 90.20M | 71.65M | 35.93M | 25.73M | 21.50M |
| Research & Development | 38.72M | 63.39M | 193.66M | 260.95M | 219.25M | 201.35M | 173.89M | 141.71M | 129.16M | 168.52M | 120.58M | 114.00M | 98.85M |
| Other Expenses | 2.74M | n/a | n/a | -1.61M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 113.46M | 130.47M | 292.95M | 369.61M | 325.33M | 298.41M | 269.48M | 226.22M | 219.37M | 240.17M | 156.51M | 139.72M | 120.34M |
| Interest Expense | 2.35M | 6.37M | 46.89M | 44.59M | 31.86M | 10.48M | 8.55M | 1.40M | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | 5.10M | 8.00M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 113.46M | 130.47M | 292.95M | 369.61M | 325.33M | 299.12M | 275.51M | 229.12M | 224.03M | 244.23M | 156.51M | 139.72M | 124.19M |
| Income Tax | 5.92M | 9.00K | -151.00K | -8.52M | -5.22M | -10.56M | 13.69M | 10.11M | 951.00K | 6.36M | n/a | n/a | n/a |
| Shares Outstanding (Basic) | 55.30M | 73.59M | 69.46M | 62.34M | 55.61M | 53.97M | 52.35M | 44.71M | 34.15M | 31.75M | 31.74M | 31.74M | 31.90M |
| Shares Outstanding (Diluted) | 55.30M | 73.59M | 69.46M | 62.34M | 55.61M | 53.97M | 52.35M | 44.71M | 34.15M | 31.75M | 32.26M | 32.26M | 31.90M |
| EPS (Basic) | -1 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | -4.92 | -0.3 | -3.43 |
| EPS (Diluted) | -1 | -1.26 | -2.87 | -4.46 | -4.25 | -3.99 | -5.45 | -4.26 | -5.34 | -7.46 | -4.84 | -0.3 | -3.43 |
| EBITDA | -40.87M | -79.86M | -249.39M | -294.00M | -203.29M | -212.44M | -259.14M | -176.04M | -178.77M | -228.01M | -153.63M | -6.32M | -105.49M |
| Depreciation & Amortization | 6.05M | 6.59M | 7.29M | 6.64M | 6.52M | 3.17M | 4.03M | 3.12M | 2.99M | 2.66M | 2.65M | 3.25M | 3.84M |